Author
Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, U.S.A.; Smith Breast Center, Baylor College of Medicine, Houston, U.S.A.;
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
T. D. Papageorgiou, J. Webb, A. Allam…·E. Froudarakis
This paper introduces an AI-driven neuromodulation platform that enhances and reorganizes human tongue sensorimotor networks by targeting individual network architecture.
H. Dowst, A. McOwiti, F. Zheng…·M. T. Lewis
The BCM PDX Portal manages PDX collections and integrates clinical and omics data for drug evaluation.
V. Petrosyan, L. E. Dobrolecki, L. Thistlethwaite…·M. T. Lewis
This paper identifies biomarkers of differential chemotherapy response in TNBC using a network-based approach and validates them in PDX models and clinical datasets.
Y. Gao, E. B. Kabotyanski, E. Villegas…·J. M. Rosen
This study shows PLK2 loss predicts better response to PLK1 inhibitors in triple-negative breast cancer and suggests PLK2 as a biomarker for treatment response.
J. Xia, L.-Y. Chiu, R. B. Nehring…·S. M. Rosenberg
The paper identifies DNA-damaging proteins in E. coli and their human homologs, showing they promote endogenous DNA damage and are overrepresented in cancer drivers.